{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Imunon, Inc. technically bullish or bearish?
As of June 18, 2025, Imunon, Inc. shows a mildly bullish trend due to positive daily moving averages and a bullish weekly MACD, but caution is advised due to bearish weekly RSI and Bollinger Bands signals.
Who are in the management team of Imunon, Inc.?
As of March 2022, the management team of Imunon, Inc. includes Michael Tardugno as Executive Chairman, President, and CEO, along with independent directors Dr. Donald Braun, Dr. Pok Yu Chow, Frederick Fritz, Robert Hooper, and Mr. Andreas Voss.
What does Imunon, Inc. do?
Imunon, Inc. is an oncology drug development company in the Pharmaceuticals & Biotechnology sector, with a market cap of USD 22.96 million and a recent net profit of -4 million. The company has no dividend yield and significant negative return on equity.
How big is Imunon, Inc.?
As of Jun 18, Imunon, Inc. has a market capitalization of 22.96 million, with net sales of 0.00 million and a net profit of -17.80 million. Shareholder's funds are 4.24 million and total assets are 9.72 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
